info@biomedres.us   +1 (502) 904-2126   One Westbrook Corporate Center, Suite 300, Westchester, IL 60154, USA   Site Map
ISSN: 2574 -1241

Impact Factor : 0.548

  Submit Manuscript

Editorial Open Access

Advances in the Treatment of FLT3-Mutated AML

Nahla A M Hamed*

DOI: 10.26717/BJSTR.2017.01.000139

  • Author Information Open or Close
    • Faculty of Medicine, Alexandria University, Egypt

    *Corresponding author: Nahla A M Hamed, Faculty of Medicine, Alexandria University, Egypt

Received: June 14, 2017   Published: June 16, 2017

To view the Full Article   Peer-reviewed Article PDF

Abstract

AML is a heterogeneous disease and is the most common acute leukemia in adults. It has an annual US incidence over 20,000 and death rate of over 10,000 per year. The 5-year remission rates after conventional induction therapy is 40% below 60 years and 10%-20% in older patients. FLT3-ITD mutation has been added to the WHO risk stratification as a predictor of poor prognosis. On April 28, 2017 FDA approved midostaurinin combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for treating adult newly diagnosed AML patients who are FLT3 mutation positive as detected by an FDA approved test.

Abbreviations: AML: Acute Myeloid Leukemia; CR: Complete Remission; DFS: Disease -Free Survival; OS: Overall Survival; ITD: Internal Tandem Duplication; FLT3: Fms-Like Tyrosine kinase 3; RTK: Receptor Tyrosine Kinase; TKI: Tyrosine Kinase Inhibitors; FL: FLT3 Ligand; PIM: Proviral Integration site; MDS: Myelodysplastic Syndrome; DLI: Donor Lymphocyte Infusion; ATP: Adenosine Triphosphate; PDGFR: Platelet Derived Growth Factor Receptor; VEGFR: Vascular Endothelial Growth Factor receptor; AEs: Adverse Events

Introduction | Conclusion | References |